Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

292

Participants

Timeline

Start Date

December 11, 2014

Primary Completion Date

May 25, 2016

Study Completion Date

May 25, 2016

Conditions
Influenza A
Interventions
DRUG

VX-787 300 mg

A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.

DRUG

VX-787 600 mg

A oral dose of VX-787 600 mg (formulated as 2\*300 mg tablets) will be administered over 5-6 days.

DRUG

Oseltamivir 75 mg

A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.

DRUG

Placebo

Subjects will receive matching placebo of Oseltamivir

Trial Locations (176)

Unknown

Athens

Birmingham

Gulf Shores

Huntsville

Scottsboro

Harrisburg

Phoenix

Anaheim

Burbank

Canoga Park

Chula Vista

El Cajon

Encino

Fresno

Garden Grove

Harbor City

Huntington Beach

La Mesa

Lomita

Long Beach

Norwalk

Oakland

Oceanside

Paramount

San Diego

Santa Monica

Tustin

Upland

Colorado Springs

Northglenn

Washington D.C.

Boca Raton

Boynton Beach

Bradenton

Brooksville

Chiefland

Clearwater

Coral Gables

Doral

Edgewater

Fort Myers

Hialeah

Homestead

Jacksonville

Kissimmee

Lake Worth

Lakeland

Long Beach Resort

Miami

New Port Richey

North Miami Beach

Orlando

Ormond Beach

Pembroke Pines

Sarasota

St. Petersburg

Tampa

West Palm Beach

Atlanta

Columbus

Anderson

Idaho Falls

Meridian

Anderson

Muncie

Newburgh

Council Bluffs

Overland Park

Bardstown

Hazard

Eunice

Mandeville

Shreveport

Oxon Hill

Worcester

Belton

Niles

Troy

St Louis

Fremont

Las Vegas

Berlin

Brooklyn

New York

Rochester

Rosedale

Advance

Hickory

Morehead City

Morganton

Salisbury

Akron

Dayton

Hilliard

Huber Heights

Tulsa

Harleysville

Jenkintown

Philadelphia

Warminster

East Providence

Johnston

Greer

Laurens

Mt. Pleasant

Rock Hill

Simpsonville

Rapid City

Bristol

Amarillo

Arlington

Austin

Baytown

Carrollton

Corpus Christi

Dallas

Fort Worth

Houston

Humble

Katy

Plano

San Antonio

Tomball

Clinton

Salt Lake City

South Jordan

Alexandria

La Crosse

Milwaukee

Borgerhout

Linkebeek

Massemen

Wichelen

Sofia

Veliko Tarnovo

Calgary

West Vancouver

Mount Pearl

Brampton

Newmarket

Toronto

Mirabel

Montreal

Saint-Jérôme

Trois-Rivières

Paide

Saku

Tallinn

Tartu

Võru

Berlin

Essen

Goch

Hamburg

Stuhr

Balvi

Daugavpils

Jelgava

Jēkabpils

Kuldīga

Lielvārde

Riga

Toa Baja

Boksburg

Breyten

Cape Town

Durban

Johannesburg

Kempton Park

Krugersdorp

Middelburg

Moloto South

Pretoria

Thabazimbi

Vanderbijlpark

Worcester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

Janssen Research & Development, LLC

INDUSTRY